bims-fagtap Biomed News
on Phage therapies and applications
Issue of 2025–08–03
nine papers selected by
Luca Bolliger, lxBio



  1. Pharmaceutics. 2025 Jun 24. pii: 820. [Epub ahead of print]17(7):
      Multidrug-resistant (MDR) bacterial infections present a major challenge in cancer therapy, particularly for immunocompromised patients undergoing chemotherapy, radiation, or surgery. These infections often arise from prolonged antibiotic use, hospital-acquired pathogens, and weakened immune defenses, leading to increased morbidity and mortality. As conventional antibiotics become less effective against MDR strains, there is an urgent need for alternative treatment options. This review highlights phage therapy as a promising approach to managing MDR bacterial infections in cancer patients. Once widely used, phage therapy has recently regained attention as a targeted antimicrobial strategy that can specifically eliminate harmful bacteria while preserving the beneficial microbiota. Phages work by directly lysing bacteria, disrupting biofilms, and synergizing with antibiotics to restore bacterial susceptibility. These mechanisms make phage therapy especially appealing for treating infections that complicate cancer treatments. However, the clinical application of phage therapy faces challenges such as variability in phage-host interactions, regulatory hurdles, and immune responses in patients. This review identifies gaps in current research regarding the use of phage therapy for MDR infections in cancer patients. By examining recent innovations, therapeutic mechanisms, and associated limitations, we provide valuable insights into the potential of phage therapy for improving infection management in oncology. Future research should focus on refining phage delivery methods, assessing long-term safety, and exploring combination therapies to maximize clinical efficacy. Overcoming these challenges could position phage therapy as a valuable complement to existing antimicrobial strategies in cancer care.
    Keywords:  bacteriophage-based treatment; cancer-associated infections; multidrug-resistant (MDR) infections; oncology infectious disease management; phage therapy
    DOI:  https://doi.org/10.3390/pharmaceutics17070820
  2. Brief Funct Genomics. 2025 Jan 15. pii: elaf011. [Epub ahead of print]24
      The misuse and overprescription of antibiotics have accelerated the rise of antimicrobial resistance (AMR), rendering many antibiotics ineffective and leading to significant clinical challenges. The conventional treatment methods have become progressively challenging, posing a threat of evolving into an impending silent pandemic. The long track record of bacteriophages combating bacterial infections has renewed hope into the potential therapeutic benefits of bacteriophages. Bacteriophage therapy offers a promising alternative to antibiotics, particularly against multidrug-resistant (MDR) pathogens. This article explores the promise of phages as a potential means to combat superbugs from the perspective of the genomic and transcriptomic landscape of the phages and their bacterial host. Advances in bacteriophage genomics have expedited the detection of new phages and AMR genes, enhancing our understanding of phage-host interactions and enabling the identification of potential treatments for antibiotic-resistant bacteria. At the same time, holo-transcriptomic studies hold potential for discovering disease and context-specific transcriptionally active phages vis-à-vis disease severity. Holo-transcriptomic profiling can be applied to investigate the presence of AMR-bacteria, highlighting COVID-19 and Dengue diseases, in addition to the globally recognized ESKAPE pathogens. By simultaneously capturing phage, bacterial and host transcripts, this approach enables a better comprehension of the bacteriophage dynamics. Moreover, insight into these defence and counter-defence interactions is essential for augmenting the adoption of phage therapy at scale and advancing bacterial control in clinical settings.
    Keywords:  AMR; Holo-transcriptomics; bacteriophages; disease severity; genomics; phage therapy
    DOI:  https://doi.org/10.1093/bfgp/elaf011
  3. Viruses. 2025 Jul 10. pii: 971. [Epub ahead of print]17(7):
      Microbial infections are an escalating global health threat, driven by the alarming rise of antimicrobial resistance (AMR), which has made many conventional antibiotics increasingly ineffective and threatens to reverse decades of medical progress. The rapid emergence and spread of multidrug-resistant bacteria have severely limited treatment options, resulting in increased morbidity, mortality, and healthcare burden worldwide. In response to these challenges, phage therapy is regaining interest as a promising alternative. Bacteriophages, the most abundant biological entities, have remarkable specificity toward their bacterial hosts, enabling them to selectively eliminate pathogenic strains. Phage therapy presents several advantages over conventional antibiotics, which include minimal disruption to the microbiome and a slower rate of resistance development. Among the various sources of phages, the marine environment remains one of the least explored. Given their adaptation to saline conditions, high pressure, and variable nutrient levels, marine bacteriophages mostly exhibit enhanced environmental stability, broader host ranges, and distinct infection mechanisms, thus making them highly promising for therapeutic purposes. This review explores the growing therapeutic potential of marine bacteriophages by examining their ecological diversity, biological characteristics, infection dynamics, and practical applications in microbial disease control. It also deals with emerging strategies such as phage-antibiotic synergy, genetic engineering, and the use of phage-derived enzymes, alongside several challenges that must be addressed to enable clinical translation and regulatory approval. Advancing our understanding and application of marine phages presents a promising path in the global fight against AMR and the development of next-generation antimicrobial therapies.
    Keywords:  antimicrobial resistance; marine bacteriophage; phage cocktail; phage therapy; phage-derived enzymes; phage–antibiotic synergy
    DOI:  https://doi.org/10.3390/v17070971
  4. Arch Microbiol. 2025 Jul 31. 207(9): 208
      Diabetic wounds present a persistent clinical challenge due to delayed healing and an increased risk of infection and complications. The rising global prevalence of diabetes and the associated burden of chronic, non-healing wounds highlight the urgent need for innovative and effective therapeutic strategies. Recent research has underscored the critical yet often overlooked role of the skin microbiome in modulating wound healing outcomes. This review explores the complex interactions between the skin microbiome and diabetic wound healing, aiming to inform the development of microbiome-based interventions. The review begins by outlining the composition and physiological functions of the skin microbiome, emphasizing its roles in maintaining cutaneous homeostasis, immune regulation, and barrier integrity. It then examines how diabetes-induced hyperglycemia disrupts microbial balance, leading to dysbiosis, impaired immune responses, and increased colonization by opportunistic pathogens. These alterations contribute to the formation of persistent biofilms, chronic inflammation, impaired angiogenesis, and ultimately, delayed wound repair. Mechanisms by which the microbiome exacerbates wound pathology are discussed, alongside emerging therapeutic strategies targeting the wound microbiota. These include probiotics, prebiotics, bacteriophage therapy, antimicrobial peptides, and microbiome-responsive dressings. Innovative approaches such as photoimmuno-antimicrobial therapies and advanced drug delivery systems are also considered for their potential to enhance treatment efficacy. Despite these promising developments, significant challenges remain in deciphering the full complexity of microbiome-host interactions and translating this knowledge into clinical practice. The review emphasizes the future potential of personalized, microbiome-based therapies tailored to individual microbial profiles and advocates for a precision medicine approach to diabetic wound care. Additionally, it highlights the need for further research into non-bacterial components of the microbiome and the integration of multi-omics technologies with advanced wound management strategies.
    Keywords:  Biofilm pathogenesis; Chronic diabetic wound; Microbiome dysbiosis; Microbiome-Targeted dressings; Phage therapy; Tissue regeneration
    DOI:  https://doi.org/10.1007/s00203-025-04399-9
  5. Int J Antimicrob Agents. 2025 Jul 30. pii: S0924-8579(25)00140-2. [Epub ahead of print] 107585
      The rising incidence of colorectal cancer (CRC), particularly among young individuals, necessitates urgent preventive and therapeutic strategies to reduce mortality and financial burdens associated with CRC treatment. According to studies, gut dysbiosis is associated with CRC, indicating that restoration to a healthy gut microbiota can improve CRC outcomes. Conventional antibiotics can rapidly eliminate CRC-associated gut microbiota, however, their lack of taxonomic precision results in non-selective elimination of both pro-tumoral and antineoplastic bacteria. In this review, we explore the potential of phage therapy to specifically target and eliminate CRC-associated bacteria, thereby mitigating their role in CRC pathogenesis. Tailored phage therapy, including phage cocktails and Fecal Microbial Transplantation (FMT), has shown promise in treating various diseases. As the efficacy of FMT is met with safety concerns, we highlight in this review how fecal viral transplantation (FVT) offers a safer alternative by using filtered fecal samples devoid of intact bacteria that would cause adverse effects. As a relatively new field with complex host-phage interactions, FVT requires further research to fully understand its potential and safety profile. Despite its potential for modulating the gut microbiota and improving CRC treatment, phage therapy still requires more clinical studies and experimental evidence to further establish its efficacy and safety in CRC patients.
    Keywords:  Colorectal cancer (CRC); Fecal viral transplantation (FVT); Gut Virome; Gut dysbiosis; Phage therapy
    DOI:  https://doi.org/10.1016/j.ijantimicag.2025.107585
  6. mSphere. 2025 Jul 28. e0019825
      While many studies have examined the bacterial taxa associated with dental caries, the most common chronic infectious disease, little is known about the caries-associated virome. In this study, the salivary viromes of 21 children with severe caries (>2 dentin lesions) and 23 children with healthy dentition were examined. A total of 2,485 viral metagenome-assembled genomes (vMAGs) were identified, binned, and quantified from the metagenomic assemblies. These vMAGs were mostly phages and represented 1,865 unique species-level viral operational taxonomic units (vOTUs), of which 478 appear to be novel. The metagenomes were also queried for all 3,858 unique species-level vOTUs of DNA viruses with a human host on NCBI Virus; however, all but Human betaherpesvirus 7 were at very low abundance in the saliva. The oral viromes of the children with caries exhibited significantly different beta diversity compared to the oral virome of the children with healthy dentition; several vOTUs predicted to infect Haemophilus and Neisseria were strongly correlated with health, and five vOTUs predicted to infect Saccharibacteria, Prevotella, and Veillonella were correlated with caries. Co-occurrence analysis indicated that the phage typically co-occurred with both their predicted hosts and with bacteria that were themselves associated with the same disease status. Overall, this study provided the sequences of 35 complete or nearly complete novel oral phages and illustrated the potential significance of the oral virome in the context of dental caries, which has been largely overlooked. This work represents an important step toward the identification and study of phage therapy candidates that treat or prevent caries pathogenesis.IMPORTANCEDental caries is the most common chronic infectious disease worldwide and is caused by dysbiosis of the oral microbiome featuring an increased abundance of acid-tolerant, acid-producing, and biofilm-forming bacteria. The oral microbiome also contains viruses; however, very little is known about the caries-associated virome. In this study, the salivary virome of children with severe caries was compared to the salivary virome of children with healthy dentition. The metagenomes contained a total of 1,865 unique species-level viral operational taxonomic units (vOTUs), of which 478 appeared to be novel. The viromes from the children with caries were significantly different than the viromes from the children with healthy teeth, and several health- and disease-associated vOTUs were identified. This study illustrated the potential importance of the oral virome in the context of dental caries and serves as a step towards a better understanding of oral inter-kingdom interactions and identification of potential phage-based caries therapeutics.
    Keywords:  bacteriophages; dental caries; oral microbiome
    DOI:  https://doi.org/10.1128/msphere.00198-25
  7. Expert Rev Anti Infect Ther. 2025 Aug 01.
       INTRODUCTION: Catheter-associated urinary tract infections (CAUTIs) are among the most prevalent hospital-acquired infections, posing a serious clinical and economic burden, particularly in the context of rising antibiotic resistance. Biofilm formation on indwelling catheters by multidrug-resistant uropathogens further complicates treatment and prevention, underscoring the urgent need for alternative, non-antibiotic solutions.
    AREAS COVERED: This article explores the potential of bacteriophage- and enzybiotic-coated urinary catheters as an innovative strategy to prevent recurrent bacterial infections. We review the clinical significance of biofilm formation on the surface of urinary catheters, the role of phages and their lytic enzymes in disrupting biofilms, and the clinical evidence supporting the efficacy of phage therapy. The reference list was compiled through a structured search of peer-reviewed studies and case reports, particularly from recent years, available in the PubMed database.
    EXPERT OPINION: Phage- and enzybiotic-functionalized catheters represent a promising non-antibiotic approach to CAUTI prevention. These biological agents offer targeted antibacterial activity, disrupt biofilms, and reduce the risk of drug resistance development. Their integration into catheter design may significantly improve infection control, reduce antibiotic use, and align with global antimicrobial stewardship goals. However, clinical standardization and regulatory clarity are crucial for advancing their implementation in routine clinical practice.
    Keywords:  Biofilm formation; enzybiotics; multidrug resistance; phage therapy; urinary tract infection; urological catheters
    DOI:  https://doi.org/10.1080/14787210.2025.2541717
  8. J Med Microbiol. 2025 Aug;74(8):
      Background.Achromobacter xylosoxidans and Pseudomonas aeruginosa are two pathogens that cause persistent airway infections in individuals with cystic fibrosis (CF). The persistence of P. aeruginosa is partly due to a high capacity to form biofilms and the ability to exert antagonism against other bacteria. Loss of microbial diversity in conjunction with chronic P. aeruginosa colonization is strongly correlated with low lung function in CF. A. xylosoxidans and P. aeruginosa are frequently co-isolated in CF airway cultures. This study aims to investigate the reciprocal effects on growth inhibition and biofilm formation between P. aeruginosa and A. xylosoxidans in vitro.Method. Six isolates of A. xylosoxidans, isolated from three CF patients in early and late stages of a chronic infection, were cultured together with a CF isolate of P. aeruginosa. Biofilm formation was assessed using a microtiter assay and crystal violet staining. Quantitative PCR was used to quantify species proportions in biofilms. Growth curves were performed to compare planktonic growth rates.Results. Three A. xylosoxidans isolates, all of which were from early-stage infections, inhibited biofilm formation of P. aeruginosa. The inhibition was concentration-dependent and required the interaction of live bacteria during the early stages of biofilm development. The inhibitory effect was not caused by nutrient depletion of the planktonic cells. The selected A. xylosoxidans isolate had a stronger capacity to adhere to plastic surfaces compared to the P. aeruginosa isolate.Conclusions . A. xylosoxidans can inhibit P. aeruginosa biofilm formation in vitro. The observed effect requires active interactions between live cells during the attachment stage of biofilm formation, possibly due to differences in adhesion capacity.
    Keywords:  Achromobacter xylosoxidans; Pseudomonas aeruginosa; biofilm; cystic fibrosis; polymicrobial interactions
    DOI:  https://doi.org/10.1099/jmm.0.002051
  9. Antibiotics (Basel). 2025 Jul 20. pii: 728. [Epub ahead of print]14(7):
      About a quarter of the world's population is infected with Mycobacterium tuberculosis. Growing antibiotic resistance by this microorganism is a major problem in the therapy of the disease. M. avium-M. intracellulare that emerged as a major opportunistic infection of HIV/AIDS continues to afflict immunocompromised individuals. We describe the use of liposome-encapsulated antibiotics in the experimental and clinical therapy of mycobacterial infections, as well as recent experimental liposomal vaccines against tuberculosis. Liposome-mediated intravenous or inhalational delivery of antibiotics enhances the antibacterial effects of the drugs, particularly for infections of resident macrophages, where the liposomes are passively targeted. Despite experimental successes of liposomal antibiotics in the treatment of mycobacterial and other bacterial infections, applications of this method to the clinic have been lagging. This review underscores the significance of liposomes in the treatment of mycobacterial infections, encompassing their synthesis methods, limitations, and both preclinical and clinical studies, providing guidance for the development of future therapeutic approaches and innovative antimicrobial strategies.
    Keywords:  antibiotics; antimycobacterial agents; bacterial infections; liposomes; tuberculosis; tuberculosis vaccines
    DOI:  https://doi.org/10.3390/antibiotics14070728